Copper Histidine Therapy for Menkes Diseases

Key facts

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Principal Investigator

Stephen G Kaler, M.D.

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Intervention

Copper Histidine(drug)

Enrollment

60 enrolled

Eligibility

All sexes

Timeline

1990 – 2013

Study locations (1)

• National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Menkes disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07398508
  Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease.
  Stephen G. Kaler
• ACTIVE NOT RECRUITINGNANCT04337684
  Long Term Follow-up on Menkes Disease Patients
  Sentynl Therapeutics, Inc.

See all trials for Menkes disease →